ReviewESMO gastrointestinal oncology2026
Advances in anal cancer treatment: current standards, the role of immunotherapy and emerging strategies.
Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rewriting the future of anal cancer care: From disparities to data-driven decisions.ESMO gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Squamous-cell carcinoma of the anus (SCCA), primarily driven by human papillomavirus infection, has seen limited treatment advancements, with current options mainly comprising chemoradiotherapy for localized disease and chemotherapy for advanced cases. However, the rise of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has opened new therapeutic avenues for this rare malignancy. This review explores the current standard of care and the evolving role of immunotherapy in managing SCCA. We discuss the results of key clinical trials, including findings from anti-Programmed cell death protein 1 (anti-PD-1)/anti-Programmed death-ligand 1 (anti-PD-L1) therapies, and ongoing research efforts focused on identifying predictive biomarkers for treatment response. Despite challenges, immunotherapy offers significant promise for improving outcomes in patients with advanced and recurrent anal cancer, potentially transforming the standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.